CoChat
Sign Up
Cited by 92Schizophrenia research and treatmentTreatment of Major DepressionBipolar Disorder and Treatment

Antidepressants for people with both schizophrenia and depression

Open access
Whitehead, Caroline, Moss, Susannah, Cardno, Alastair, Lewis, Glyn, Furtado, Vivek A·2002·Cochrane Database of Systematic Reviews
DOI 10.1002/14651858.cd002305PMC PMC6669259
Open this paper in CoChat — free accountOpen PDF

Abstract

BACKGROUND: Depressive symptoms, often of substantial severity, are found in 50% of newly diagnosed suffers of schizophrenia and 33% of people with chronic schizophrenia who have relapsed. Depression is associated with dysphoria, disability, reduction of motivation to accomplish tasks and the activities of daily living, an increased duration of illness and more frequent relapses. OBJECTIVES: To determine the clinical effects of antidepressant medication for the treatment of depression in people who also suffer with schizophrenia. SEARCH STRATEGY: We undertook electronic searches of the Cochrane Schizophrenia Group's Register (October 2000), ClinPsych (1988-2000), The Cochrane Library (Issue 3, 2000), EMBASE (1980-2000) and MEDLINE (1966-2000). This was supplemented by citation searching, personal contact with authors and pharmaceutical companies. SELECTION CRITERIA: All randomised clinical trials that compared antidepressant medication with placebo for people with schizophrenia or schizoaffective disorder who were also suffering from depression. DATA COLLECTION AND ANALYSIS: Data were independently selected and extracted. For homogeneous dichotomous data the fixed effects risk difference (RD), the 95% confidence intervals (CI) and, where appropriate, the number needed to treat (NNT) were calculated on an intention-to-treat basis. For continuous data, reviewers calculated weighted mean differences. Statistical tests for heterogeneity were also undertaken. MAIN RESULTS: Eleven studies met the inclusion criteria. All were small, and randomised fewer than 30 people to each group. Most included people after the most acute phase of psychosis and investigated a wide range of antidepressants. The quality of reporting varied a great deal. For the outcome of 'no important clinical response' antidepressants were significantly better than placebo (n=209, 5 RCTs, summary risk difference fixed effects -0.26, 95% CI -0.39 to -0.13, NNT 4 95% CI 3 to 8). The depression score at the end of the trial, as assessed by the Hamilton Rating Scale (HAM-D), seemed to suggest that using antidepressants was beneficial, but this was only statistically significant when a fixed effects model was used (n=261, 6 RCTs, WMD fixed effects -2.2 95% CI -3.8 to -0.6; WMD random effects -2.1 95% CI -5.04 to 0.84). There was no evidence that antidepressant treatment led to a deterioration of psychotic symptoms in the included trials. Heterogeneous data on 'any adverse effect' are equivocal (n=110, 2 RCTs, RD fixed 0.11 CI -0.03 to 0.25, Chi square 7.5, df=1, p=0.0062). In one small study extrapyramidal adverse effects were reported less often by those allocated to antidepressant (n=52, 1 RCT, RD fixed -0.28 CI -0.5 to -0.04). Only about 10% of people left these studies by 12 weeks. There was no apparent difference between those allocated placebo and those given an antidepressant (n=426, 10 RCTs, RD fixed 0.04 CI -0.02 to 0.1). REVIEWER'S CONCLUSIONS: Overall, the literature was of poor quality, and only a small number of trials made useful contributions. Though our results provide some evidence to indicate that antidepressants may be beneficial for people with depression and schizophrenia, the results, at best, are likely to overestimate the treatment effect, and, at worst, could merely reflect selective reporting of statistically significant results and publication bias. At present, there is no convincing evidence to support or refute the use of antidepressants in treating depression in people with schizophrenia. We need further well-designed, conducted and reported research to determine the best approach towards treating depression in people with schizophrenia.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/14651858.cd002305

Cites

87 of 87 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 33

  1. Addington 2002a {published data only} Addington DE, Addington JM, Patten SB, Remington GJ, Moamai J, Labelle A, et al. Sertraline for depression in remitted schizophrenia. Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA. 2002.
  2. Berk 2002 {published data only} Berk M, Ichim C, Brook S. Mirtazepine treatment of negative schizophrenia. Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA. 2002.
  3. Chen 2007 {published data only} Chen K. Fluoxetine in the treatment of schizophrenic depression [氟⻄汀治疗精神分裂症后抑郁的研究]. Medical Journal of Chinese People's Health [######] 2007;19(11):486, 488.
  4. Fitzgerald PB, Filia S, De Castella A, McBain N, Kapur S, Kulkarni J. Amoxapine in schizophrenia: a negative double- blind controlled trial. Journal of Clinical Psychopharmacology 2004;24(4):448-50. [MEDLINE: 15232339]
  5. Gerson 1970 {published data only} Gerson F. Ketipramine versus imipramine. Psychopharmacology Bulletin 1970;7(2):49-52.
  6. Kim 2006 {published data only} Kim H, Lee KJ, Lee SH. Citalopram for depressive symptoms in chronic schizophrenia. Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25; Toronto, Canada. 2006.
  7. Krumholz 1968 {published data only} Krumholz. MO-1255 versus Imipramine. Psychopharmacology Bulletin 1968;5(2):49-51.
  8. Lehmann 1970 {published data only} Lehmann HE, Ban TA. Doxepin in schizophrenics. Psychopharmacology Bulletin 1970;7(2):55-7.
  9. Liu 2002 {published data only} Liu Y, Xu M, Zheng S. A clinical control study of venlafaxine and clomipramine in the treatment of post-schizophrenic depression [万拉法新与氯丙咪嗪治疗精神分裂症后抑 郁对照研究]. Shandong Archives of Psychiatry [######] 2002;15(4):216-8.
  10. Liu 2003 {published data only} Liu Y, Feng W, Xu M. A comparative study of vanlafaxine and fluoxetine in the treatment of post-schizophrenic depression. Medical Journal of Chinese Civil Administration 2003;15(6):327-9.
  11. Ou 2007 {published data only} Ou G. A study on the adjunct effects of the anti-depression drug in treating schizophrenia with anxiety and depression symptom [抗抑郁药对伴焦虑抑郁症状精神分裂症的辅助 治疗效应]. Chinese Journal of Health Psychology [#########] 2007;15(2):159-60.
  12. Postel M, Czermack M, Postel J. Depressive forms of schizophrenia: experiment of treatment by chlorimipramine. L'Encephale 1971;60(4):312-34.
  13. Ren 2004 {published data only} Ren X, Zhen S, Fu X. A comparative study of amitriptyline plus cognitive therapy in the treatment of post-schizophrenic depression. Shanghai Archives of Psychiatry [######] [######] 2004;16(2):83-5.
  14. Ruan 2008 {published data only} Ruan S, Zheng W, Du L. A control study of clozapine plus fluoxetine in schizophrenia with depressive symptoms [氯氮平 联合氟⻄汀治疗精神分裂症伴抑郁症状对照研究]. Journal of Clinical Psychosomatic Diseases [########] 2008;14(3):211-3.
  15. Tang 2005 {published data only} Tang Y. Clinical comparative study of venlafaxine and chlorine the microphone Paming treatment of schizophrenia, depression [博乐欣和氯咪帕明治疗精神分裂症后抑郁的临床对⽐研究]. ###### 2005;6(21):39-40.
  16. Warawat 2544 {published data only} Warawat C. Efficacy of olanzapine versus olanzapine combined with fluvozamine in acute-phase schizophrenia [############# olanzapine ############## olanzapine ####### fluvoxamine #########################]. Journal of Psychiatric Association of Thailand 2544;46(4):275-87.
  17. Wu 2006 {published data only} Wu X, Gao Z, Li Z. A control study of antidepressants adjuvant in schizophrenics with anxious and depressive symptoms [抗 抑郁剂辅助治疗精神分裂症伴焦虑抑郁症状患者对照研 究]. Journal of Clinical Psychosomatic Diseases [########] 2006;12(4):258-9.
  18. Xu 2007 {published data only} Xu Q. Control study of citalopram and clomipramine in the treatment of schizophrenia Depression [⻄酞普兰和氯丙咪 嗪治疗精神分裂症后抑郁对照研究]. Shandong Archives of Psychiatry [######] 2007;20(2):101-2.
  19. Yao W-H, Zhu Y-H, Li B, Feng W-C. Curative effect and safety of tatinol in improving the negative emotions of patients with schizophrenia [达体朗改善精神分裂症患者负性情绪的疗效及 安全性]. Modern Rehabilitation [现代康复] 2005; Vol. 9, issue 28:26-8.
  20. Zhou 2005 {published data only} Zhou G. A clinical study of fluoxetine combined with supportive psychotherapy in post-schizophrenia depression. Journal of Clinical Psychosomatic Diseases [########] 2005;11(3):209-10.
  21. 刘守梅 2009 {published data only} 刘守梅. Duloxetine and fluoxetine in the treatment of schizophrenia with depressive control study [Google Translate] [度洛⻄汀与氟⻄汀治疗精神分裂症后抑郁对照研究]. Journal of Military Surgeon in Southwest China 2009;11(5):840-1.
  22. 周⼴⽟ 2011 {published data only} 周⼴⽟, 荣敏. Paroxetine combined with lithium in 24 cases of refractory depression efficacy [帕罗⻄汀合并碳酸锂对 24 例难治性抑郁症疗效]. 中国⺠康医学 2011; Vol. 23, issue 15:1899-90.
  23. 孙祺章 2000 {published data only} 孙祺章, 余国汉, 张教东, 丁国安. Control study of domestic venlafaxine and amitriptyline in the treatment of schizophrenia, depression [国产万拉法新和阿⽶替林治疗精神分裂症后抑 郁对照研究]. Chinese Journal of Nervous and Mental Diseases 2000;26(5):301-2.
  24. 张传海 2007 {published data only} 张传海. Depression controlled study of sertraline and venlafaxine in the treatment of schizophrenia [舍曲林与万拉 法新治疗精神分裂症后抑郁对照研究]. Chinese Journal of Primary Medicine Pharmacy [######] 2007;14(2):286-8.
  25. 张新平 2009 {published data only} 张新平, 刘⾦鹏, 余志刚, 庄建军, ⽩颖, 范勇. Shun Qi Decoction Treating depression a er 30 cases of schizophrenia [Google Translate] [顺⽓解郁汤加减治疗精神分裂症后抑郁 30 例]. Henan Traditional Chinese Medicine 2009;29(10):1003-4.
  26. 李兰芳 2010 {published data only} 李兰芳, 曹⻘, 陈宇晖. Venlafaxine and amitriptyline combined controlled study of risperidone in the treatment of schizophrenia with depressive symptoms [⽂拉法⾟与阿⽶替 林分别合并利培酮治疗精神分裂症伴抑郁症状的对照研究]. ###### 2010;11(08):31-4.
  27. ⽪玥玥 2010 {published data only} ⽪玥玥. Citalopram and venlafaxine in the treatment of schizophrenia, depression-control study [⻄酞普兰与⽂拉法⾟ 治疗精神分裂症后抑郁的对照研究]. 中国实⽤神经疾病杂志 2010; Vol. 13, issue 24:34-5.
  28. 耿⽟⾠ 2008 {published data only} 耿⽟⾠, 蒋⽟兰, 耿姝霞. Comparative study of citalopram and fluoxetine in the treatment of mental illness, depression and residual depression [⻄酞普兰与氟⻄汀治疗精神病后抑郁及 残留期抑郁的对⽐研究]. ###### 2008;5(25):65-6.
  29. 莫迪 2011 {published data only} 莫迪. Citalopram treatment of schizophrenia and depression [⻄酞普兰治疗精神分裂症后抑郁的疗效观察]. 中国⺠康医 学 2011; Vol. 23, issue 16:2003-4.
  30. 韩卫军 2009 {published data only} 韩卫军, 孙桂荷. Sulpiride and buspirone hydrochloride tablets in the treatment of schizophrenia and the effect of depression a er double-blind controlled study side effects [Google Translate] [舒必利与盐酸丁螺环酮⽚治疗精神分裂症 后抑郁的疗效和副反应双肓对照研究]. 辽宁中医药⼤学学报 2009; Vol. 11, issue 7:131.
  31. ⻢军 2010 {published data only} ⻢军, 刘永义, 殷朝辉, 张媛. Escitalopram and maprotiline treatment of depression a er control study of schizophrenia [Google Translate] [艾司⻄酞普兰和⻢普替林治疗分裂症后抑 郁的对照研究]. Nei Moivgol Medical Journal 2010;42(2):171-3.
  32. ⻢振武 2003 {published data only} ⻢振武, 张爱景. 133 cases of fluoxetine in the treatment of schizophrenia, depression [氟⻄汀治疗精神分裂症后抑郁 133 例]. Chinese Journal of Clinical Rehabilitation 2003;24:3333. Cochrane Database of Systematic Reviews short term treatment of major depression. British Journal of Psychiatry 2000;176:421-8.
  33. Clarke M, Oxman AD. Cochrane Collaboration Handbook. The Cochrane Library. Oxford: Update So ware, 2002, issue 1.

Cited by

Sorted by citations

Related

Authors
Whitehead, C., Moss, S., Cardno, A., Lewis, G., & Furtado, V. A.
Affiliations
  • University of Bristol (GB)
  • Cardiff University; Occupational Health Psychology; 63 Park Place Cathays Cardiff UK CF10 3AS
  • University of Leeds (GB)
  • Rampton Hospital (GB)
ORCID
Venue
Cochrane Database of Systematic Reviews
Publisher
Wiley
Published
2002-04-22
Volume
2013
Issue
4
Pages
CD002305-CD002305
ISSN
  • 1361-6137 (ISSN-L)
  • 1465-1858
DOI
10.1002/14651858.cd002305
PMC
PMC6669259
OpenAlex
W1919383023
Cited by
92
References
87
Citations by year
2025: 5 · 2024: 3 · 2023: 1 · 2022: 1 · 2021: 4 · 2020: 1 · 2019: 3 · 2018: 5 · 2017: 4 · 2016: 4 · 2015: 10 · 2014: 5 · 2013: 11 · 2012: 6
FWCI
0.49
Type
journal article
Language
en
Open access
Locations
  • Cochrane Database of Systematic Reviews (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • UCL Discovery (University College London) (submittedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
Keywords
antidepressants, schizophrenia, depression, schizoaffective disorder, comorbid depression, antidepressant efficacy, placebo comparison, relapse, treatment response, Hamilton Depression Rating Scale, adverse effects, relapse prevention, cost-effectiveness, cost-effectiveness analysis, number needed to treat, number needed to harm, number needed to benefit
MeSH terms
Antidepressive Agents, Depression, Humans, Schizophrenia, Antipsychotic Agents, Randomized Controlled Trials as Topic, Chemotherapy, Adjuvant

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review